JP2019501926A - 家塵ダニ由来アレルゲンによる過敏反応免疫調節剤 - Google Patents
家塵ダニ由来アレルゲンによる過敏反応免疫調節剤 Download PDFInfo
- Publication number
- JP2019501926A JP2019501926A JP2018536115A JP2018536115A JP2019501926A JP 2019501926 A JP2019501926 A JP 2019501926A JP 2018536115 A JP2018536115 A JP 2018536115A JP 2018536115 A JP2018536115 A JP 2018536115A JP 2019501926 A JP2019501926 A JP 2019501926A
- Authority
- JP
- Japan
- Prior art keywords
- der
- house dust
- dust mite
- derived
- allergen
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000013566 allergen Substances 0.000 title claims abstract description 62
- 239000000428 dust Substances 0.000 title claims abstract description 45
- 208000026935 allergic disease Diseases 0.000 title claims abstract description 32
- 239000002955 immunomodulating agent Substances 0.000 title abstract description 14
- 230000002584 immunomodulator Effects 0.000 title abstract description 12
- 229940121354 immunomodulator Drugs 0.000 title abstract description 12
- 206010020751 Hypersensitivity Diseases 0.000 title description 14
- 230000009610 hypersensitivity Effects 0.000 title 1
- 241000894006 Bacteria Species 0.000 claims abstract description 38
- 239000008194 pharmaceutical composition Substances 0.000 claims abstract description 19
- 241000238713 Dermatophagoides farinae Species 0.000 claims abstract description 18
- 238000004519 manufacturing process Methods 0.000 claims abstract description 14
- 241000238740 Dermatophagoides pteronyssinus Species 0.000 claims abstract description 7
- 239000004480 active ingredient Substances 0.000 claims abstract description 7
- 230000002265 prevention Effects 0.000 claims abstract description 5
- 238000000034 method Methods 0.000 claims description 40
- 239000002158 endotoxin Substances 0.000 claims description 20
- 230000001580 bacterial effect Effects 0.000 claims description 18
- 241000607142 Salmonella Species 0.000 claims description 12
- 239000012528 membrane Substances 0.000 claims description 12
- 108090000623 proteins and genes Proteins 0.000 claims description 10
- 230000000694 effects Effects 0.000 claims description 8
- 241000588724 Escherichia coli Species 0.000 claims description 6
- 238000012258 culturing Methods 0.000 claims description 5
- 108010055622 Dermatophagoides farinae antigen f 1 Proteins 0.000 claims description 3
- 108700026220 vif Genes Proteins 0.000 claims 1
- 230000002519 immonomodulatory effect Effects 0.000 abstract description 2
- 239000000427 antigen Substances 0.000 description 58
- 108091007433 antigens Proteins 0.000 description 58
- 102000036639 antigens Human genes 0.000 description 58
- 208000006673 asthma Diseases 0.000 description 21
- 108010093965 Polymyxin B Proteins 0.000 description 17
- 229960004784 allergens Drugs 0.000 description 17
- 229920000024 polymyxin B Polymers 0.000 description 17
- 229960005266 polymyxin b Drugs 0.000 description 17
- 229920006008 lipopolysaccharide Polymers 0.000 description 14
- 210000004027 cell Anatomy 0.000 description 12
- 230000028993 immune response Effects 0.000 description 12
- 108010082995 Dermatophagoides farinae antigen f 2 Proteins 0.000 description 11
- 201000010099 disease Diseases 0.000 description 11
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 11
- 210000004379 membrane Anatomy 0.000 description 11
- 241000238711 Pyroglyphidae Species 0.000 description 10
- 239000012530 fluid Substances 0.000 description 10
- 229940046533 house dust mites Drugs 0.000 description 10
- 241000699670 Mus sp. Species 0.000 description 9
- 108020004566 Transfer RNA Proteins 0.000 description 9
- 102000004889 Interleukin-6 Human genes 0.000 description 8
- 108090001005 Interleukin-6 Proteins 0.000 description 8
- 210000001744 T-lymphocyte Anatomy 0.000 description 8
- 210000004969 inflammatory cell Anatomy 0.000 description 8
- 210000003928 nasal cavity Anatomy 0.000 description 8
- 230000002018 overexpression Effects 0.000 description 8
- 239000000243 solution Substances 0.000 description 8
- 102000004127 Cytokines Human genes 0.000 description 7
- 108090000695 Cytokines Proteins 0.000 description 7
- 241000699666 Mus <mouse, genus> Species 0.000 description 7
- 238000009169 immunotherapy Methods 0.000 description 7
- 238000010255 intramuscular injection Methods 0.000 description 7
- 239000007927 intramuscular injection Substances 0.000 description 7
- 230000028327 secretion Effects 0.000 description 7
- 206010003645 Atopy Diseases 0.000 description 6
- 230000008105 immune reaction Effects 0.000 description 6
- 230000036039 immunity Effects 0.000 description 6
- 239000002609 medium Substances 0.000 description 6
- UCSJYZPVAKXKNQ-HZYVHMACSA-N streptomycin Chemical compound CN[C@H]1[C@H](O)[C@@H](O)[C@H](CO)O[C@H]1O[C@@H]1[C@](C=O)(O)[C@H](C)O[C@H]1O[C@@H]1[C@@H](NC(N)=N)[C@H](O)[C@@H](NC(N)=N)[C@H](O)[C@H]1O UCSJYZPVAKXKNQ-HZYVHMACSA-N 0.000 description 6
- 231100000419 toxicity Toxicity 0.000 description 6
- 230000001988 toxicity Effects 0.000 description 6
- 108091032955 Bacterial small RNA Proteins 0.000 description 5
- 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 description 5
- 241000293869 Salmonella enterica subsp. enterica serovar Typhimurium Species 0.000 description 5
- 210000002540 macrophage Anatomy 0.000 description 5
- 238000005199 ultracentrifugation Methods 0.000 description 5
- 108010074328 Interferon-gamma Proteins 0.000 description 4
- 108050003558 Interleukin-17 Proteins 0.000 description 4
- 239000007983 Tris buffer Substances 0.000 description 4
- 210000000612 antigen-presenting cell Anatomy 0.000 description 4
- 238000010367 cloning Methods 0.000 description 4
- 239000003814 drug Substances 0.000 description 4
- 238000002296 dynamic light scattering Methods 0.000 description 4
- 230000014509 gene expression Effects 0.000 description 4
- 230000005847 immunogenicity Effects 0.000 description 4
- 239000000203 mixture Substances 0.000 description 4
- 239000013612 plasmid Substances 0.000 description 4
- 210000001938 protoplast Anatomy 0.000 description 4
- 230000002829 reductive effect Effects 0.000 description 4
- 210000002966 serum Anatomy 0.000 description 4
- 239000000126 substance Substances 0.000 description 4
- 210000001519 tissue Anatomy 0.000 description 4
- LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 4
- MZOFCQQQCNRIBI-VMXHOPILSA-N (3s)-4-[[(2s)-1-[[(2s)-1-[[(1s)-1-carboxy-2-hydroxyethyl]amino]-4-methyl-1-oxopentan-2-yl]amino]-5-(diaminomethylideneamino)-1-oxopentan-2-yl]amino]-3-[[2-[[(2s)-2,6-diaminohexanoyl]amino]acetyl]amino]-4-oxobutanoic acid Chemical compound OC[C@@H](C(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](CC(O)=O)NC(=O)CNC(=O)[C@@H](N)CCCCN MZOFCQQQCNRIBI-VMXHOPILSA-N 0.000 description 3
- 208000035143 Bacterial infection Diseases 0.000 description 3
- 206010012438 Dermatitis atopic Diseases 0.000 description 3
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 3
- 108090000978 Interleukin-4 Proteins 0.000 description 3
- 102000016943 Muramidase Human genes 0.000 description 3
- 108010014251 Muramidase Proteins 0.000 description 3
- MSFSPUZXLOGKHJ-UHFFFAOYSA-N Muraminsaeure Natural products OC(=O)C(C)OC1C(N)C(O)OC(CO)C1O MSFSPUZXLOGKHJ-UHFFFAOYSA-N 0.000 description 3
- 108010062010 N-Acetylmuramoyl-L-alanine Amidase Proteins 0.000 description 3
- 229930182555 Penicillin Natural products 0.000 description 3
- JGSARLDLIJGVTE-MBNYWOFBSA-N Penicillin G Chemical compound N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)CC1=CC=CC=C1 JGSARLDLIJGVTE-MBNYWOFBSA-N 0.000 description 3
- 108010013639 Peptidoglycan Proteins 0.000 description 3
- 241001591005 Siga Species 0.000 description 3
- 108060008682 Tumor Necrosis Factor Proteins 0.000 description 3
- 102000000852 Tumor Necrosis Factor-alpha Human genes 0.000 description 3
- 229940083231 american house dust mite extract Drugs 0.000 description 3
- 239000003242 anti bacterial agent Substances 0.000 description 3
- 229940088710 antibiotic agent Drugs 0.000 description 3
- 201000008937 atopic dermatitis Diseases 0.000 description 3
- 208000022362 bacterial infectious disease Diseases 0.000 description 3
- 210000004369 blood Anatomy 0.000 description 3
- 239000008280 blood Substances 0.000 description 3
- 238000005119 centrifugation Methods 0.000 description 3
- 239000002552 dosage form Substances 0.000 description 3
- 229940079593 drug Drugs 0.000 description 3
- 239000003937 drug carrier Substances 0.000 description 3
- 238000001125 extrusion Methods 0.000 description 3
- 238000001914 filtration Methods 0.000 description 3
- 238000001727 in vivo Methods 0.000 description 3
- 230000001939 inductive effect Effects 0.000 description 3
- 229960000274 lysozyme Drugs 0.000 description 3
- 239000004325 lysozyme Substances 0.000 description 3
- 235000010335 lysozyme Nutrition 0.000 description 3
- 229940049954 penicillin Drugs 0.000 description 3
- 239000013641 positive control Substances 0.000 description 3
- 230000001681 protective effect Effects 0.000 description 3
- 229960005322 streptomycin Drugs 0.000 description 3
- JKMHFZQWWAIEOD-UHFFFAOYSA-N 2-[4-(2-hydroxyethyl)piperazin-1-yl]ethanesulfonic acid Chemical compound OCC[NH+]1CCN(CCS([O-])(=O)=O)CC1 JKMHFZQWWAIEOD-UHFFFAOYSA-N 0.000 description 2
- 241000238876 Acari Species 0.000 description 2
- NLXLAEXVIDQMFP-UHFFFAOYSA-N Ammonia chloride Chemical compound [NH4+].[Cl-] NLXLAEXVIDQMFP-UHFFFAOYSA-N 0.000 description 2
- 208000012657 Atopic disease Diseases 0.000 description 2
- 208000000059 Dyspnea Diseases 0.000 description 2
- 206010013975 Dyspnoeas Diseases 0.000 description 2
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 2
- 239000007995 HEPES buffer Substances 0.000 description 2
- 101000914514 Homo sapiens T-cell-specific surface glycoprotein CD28 Proteins 0.000 description 2
- 206010061218 Inflammation Diseases 0.000 description 2
- 102100037850 Interferon gamma Human genes 0.000 description 2
- 102000008070 Interferon-gamma Human genes 0.000 description 2
- 102000015696 Interleukins Human genes 0.000 description 2
- 108010063738 Interleukins Proteins 0.000 description 2
- 208000037656 Respiratory Sounds Diseases 0.000 description 2
- 206010040047 Sepsis Diseases 0.000 description 2
- 102100027213 T-cell-specific surface glycoprotein CD28 Human genes 0.000 description 2
- 230000029662 T-helper 1 type immune response Effects 0.000 description 2
- 210000000447 Th1 cell Anatomy 0.000 description 2
- 206010047924 Wheezing Diseases 0.000 description 2
- 230000033289 adaptive immune response Effects 0.000 description 2
- 201000009961 allergic asthma Diseases 0.000 description 2
- 229940037003 alum Drugs 0.000 description 2
- 238000004458 analytical method Methods 0.000 description 2
- 238000010171 animal model Methods 0.000 description 2
- 230000003110 anti-inflammatory effect Effects 0.000 description 2
- 210000001185 bone marrow Anatomy 0.000 description 2
- 210000002798 bone marrow cell Anatomy 0.000 description 2
- 239000000969 carrier Substances 0.000 description 2
- 210000002421 cell wall Anatomy 0.000 description 2
- 230000001413 cellular effect Effects 0.000 description 2
- 239000003795 chemical substances by application Substances 0.000 description 2
- 208000037976 chronic inflammation Diseases 0.000 description 2
- 230000006020 chronic inflammation Effects 0.000 description 2
- 150000001875 compounds Chemical class 0.000 description 2
- 210000004443 dendritic cell Anatomy 0.000 description 2
- 230000004069 differentiation Effects 0.000 description 2
- 238000010790 dilution Methods 0.000 description 2
- 239000012895 dilution Substances 0.000 description 2
- 230000007893 endotoxin activity Effects 0.000 description 2
- 238000002474 experimental method Methods 0.000 description 2
- 238000009472 formulation Methods 0.000 description 2
- 229940044627 gamma-interferon Drugs 0.000 description 2
- 230000036541 health Effects 0.000 description 2
- 210000002865 immune cell Anatomy 0.000 description 2
- 230000001900 immune effect Effects 0.000 description 2
- 238000000338 in vitro Methods 0.000 description 2
- 230000006698 induction Effects 0.000 description 2
- 230000004054 inflammatory process Effects 0.000 description 2
- 238000002347 injection Methods 0.000 description 2
- 239000007924 injection Substances 0.000 description 2
- 230000015788 innate immune response Effects 0.000 description 2
- 238000007912 intraperitoneal administration Methods 0.000 description 2
- 230000000670 limiting effect Effects 0.000 description 2
- 238000011068 loading method Methods 0.000 description 2
- 210000004072 lung Anatomy 0.000 description 2
- 210000001165 lymph node Anatomy 0.000 description 2
- 230000001404 mediated effect Effects 0.000 description 2
- 238000002156 mixing Methods 0.000 description 2
- 231100000252 nontoxic Toxicity 0.000 description 2
- 230000003000 nontoxic effect Effects 0.000 description 2
- 230000008506 pathogenesis Effects 0.000 description 2
- 239000008188 pellet Substances 0.000 description 2
- 210000003200 peritoneal cavity Anatomy 0.000 description 2
- 230000008569 process Effects 0.000 description 2
- 102000004169 proteins and genes Human genes 0.000 description 2
- 230000001105 regulatory effect Effects 0.000 description 2
- 206010039083 rhinitis Diseases 0.000 description 2
- 208000024891 symptom Diseases 0.000 description 2
- AYEKOFBPNLCAJY-UHFFFAOYSA-O thiamine pyrophosphate Chemical compound CC1=C(CCOP(O)(=O)OP(O)(O)=O)SC=[N+]1CC1=CN=C(C)N=C1N AYEKOFBPNLCAJY-UHFFFAOYSA-O 0.000 description 2
- 229960005486 vaccine Drugs 0.000 description 2
- 239000011534 wash buffer Substances 0.000 description 2
- 238000005406 washing Methods 0.000 description 2
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 1
- QKNYBSVHEMOAJP-UHFFFAOYSA-N 2-amino-2-(hydroxymethyl)propane-1,3-diol;hydron;chloride Chemical compound Cl.OCC(N)(CO)CO QKNYBSVHEMOAJP-UHFFFAOYSA-N 0.000 description 1
- 108010006533 ATP-Binding Cassette Transporters Proteins 0.000 description 1
- 102000005416 ATP-Binding Cassette Transporters Human genes 0.000 description 1
- 241000588626 Acinetobacter baumannii Species 0.000 description 1
- 241000238421 Arthropoda Species 0.000 description 1
- 241000283707 Capra Species 0.000 description 1
- 244000205754 Colocasia esculenta Species 0.000 description 1
- 235000006481 Colocasia esculenta Nutrition 0.000 description 1
- 206010010744 Conjunctivitis allergic Diseases 0.000 description 1
- 229920000858 Cyclodextrin Polymers 0.000 description 1
- 201000004624 Dermatitis Diseases 0.000 description 1
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 1
- 238000012286 ELISA Assay Methods 0.000 description 1
- 241000196324 Embryophyta Species 0.000 description 1
- 208000004232 Enteritis Diseases 0.000 description 1
- 241000672609 Escherichia coli BL21 Species 0.000 description 1
- 108091033480 Escherichia coli sRNA Proteins 0.000 description 1
- 241000192125 Firmicutes Species 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Chemical compound OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- 108091033761 Hfq binding sRNA Proteins 0.000 description 1
- 241000282412 Homo Species 0.000 description 1
- 108010001336 Horseradish Peroxidase Proteins 0.000 description 1
- 238000012404 In vitro experiment Methods 0.000 description 1
- 239000000232 Lipid Bilayer Substances 0.000 description 1
- 239000006391 Luria-Bertani Medium Substances 0.000 description 1
- 239000005913 Maltodextrin Substances 0.000 description 1
- 229920002774 Maltodextrin Polymers 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 206010028741 Nasal inflammation Diseases 0.000 description 1
- 241000588650 Neisseria meningitidis Species 0.000 description 1
- 108010079246 OMPA outer membrane proteins Proteins 0.000 description 1
- 101710116435 Outer membrane protein Proteins 0.000 description 1
- 108010040201 Polymyxins Proteins 0.000 description 1
- 241000605862 Porphyromonas gingivalis Species 0.000 description 1
- 208000003251 Pruritus Diseases 0.000 description 1
- 239000012980 RPMI-1640 medium Substances 0.000 description 1
- 102000007056 Recombinant Fusion Proteins Human genes 0.000 description 1
- 108010008281 Recombinant Fusion Proteins Proteins 0.000 description 1
- 206010039085 Rhinitis allergic Diseases 0.000 description 1
- 208000036071 Rhinorrhea Diseases 0.000 description 1
- 206010039101 Rhinorrhoea Diseases 0.000 description 1
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 1
- 241000191967 Staphylococcus aureus Species 0.000 description 1
- 229930006000 Sucrose Natural products 0.000 description 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
- 230000005867 T cell response Effects 0.000 description 1
- 230000030429 T-helper 17 type immune response Effects 0.000 description 1
- 210000000068 Th17 cell Anatomy 0.000 description 1
- 108010060804 Toll-Like Receptor 4 Proteins 0.000 description 1
- 102000008233 Toll-Like Receptor 4 Human genes 0.000 description 1
- COQLPRJCUIATTQ-UHFFFAOYSA-N Uranyl acetate Chemical compound O.O.O=[U]=O.CC(O)=O.CC(O)=O COQLPRJCUIATTQ-UHFFFAOYSA-N 0.000 description 1
- 208000035868 Vascular inflammations Diseases 0.000 description 1
- 241000607626 Vibrio cholerae Species 0.000 description 1
- 210000000683 abdominal cavity Anatomy 0.000 description 1
- 239000000654 additive Substances 0.000 description 1
- 208000002205 allergic conjunctivitis Diseases 0.000 description 1
- 230000000172 allergic effect Effects 0.000 description 1
- 208000030961 allergic reaction Diseases 0.000 description 1
- 201000010105 allergic rhinitis Diseases 0.000 description 1
- 230000007815 allergy Effects 0.000 description 1
- WNROFYMDJYEPJX-UHFFFAOYSA-K aluminium hydroxide Chemical compound [OH-].[OH-].[OH-].[Al+3] WNROFYMDJYEPJX-UHFFFAOYSA-K 0.000 description 1
- 235000019270 ammonium chloride Nutrition 0.000 description 1
- 230000000890 antigenic effect Effects 0.000 description 1
- 239000003963 antioxidant agent Substances 0.000 description 1
- 230000003078 antioxidant effect Effects 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 208000010216 atopic IgE responsiveness Diseases 0.000 description 1
- 208000024998 atopic conjunctivitis Diseases 0.000 description 1
- 208000010668 atopic eczema Diseases 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 239000011230 binding agent Substances 0.000 description 1
- 230000033228 biological regulation Effects 0.000 description 1
- 230000005540 biological transmission Effects 0.000 description 1
- 230000000903 blocking effect Effects 0.000 description 1
- 239000007853 buffer solution Substances 0.000 description 1
- 239000007975 buffered saline Substances 0.000 description 1
- 238000005251 capillar electrophoresis Methods 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 230000024245 cell differentiation Effects 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 239000002299 complementary DNA Substances 0.000 description 1
- 230000001276 controlling effect Effects 0.000 description 1
- 230000001086 cytosolic effect Effects 0.000 description 1
- 238000000354 decomposition reaction Methods 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 230000007123 defense Effects 0.000 description 1
- 238000010586 diagram Methods 0.000 description 1
- 230000037213 diet Effects 0.000 description 1
- 235000005911 diet Nutrition 0.000 description 1
- 102000038379 digestive enzymes Human genes 0.000 description 1
- 108091007734 digestive enzymes Proteins 0.000 description 1
- 239000003085 diluting agent Substances 0.000 description 1
- 239000002270 dispersing agent Substances 0.000 description 1
- 238000002224 dissection Methods 0.000 description 1
- 238000009826 distribution Methods 0.000 description 1
- 231100000673 dose–response relationship Toxicity 0.000 description 1
- 238000001493 electron microscopy Methods 0.000 description 1
- 238000001962 electrophoresis Methods 0.000 description 1
- 238000004520 electroporation Methods 0.000 description 1
- 239000000839 emulsion Substances 0.000 description 1
- 238000006911 enzymatic reaction Methods 0.000 description 1
- 210000003743 erythrocyte Anatomy 0.000 description 1
- 230000029142 excretion Effects 0.000 description 1
- 239000000284 extract Substances 0.000 description 1
- 210000003608 fece Anatomy 0.000 description 1
- 238000001997 free-flow electrophoresis Methods 0.000 description 1
- 210000001035 gastrointestinal tract Anatomy 0.000 description 1
- 238000001641 gel filtration chromatography Methods 0.000 description 1
- 239000008187 granular material Substances 0.000 description 1
- 239000001963 growth medium Substances 0.000 description 1
- 230000008076 immune mechanism Effects 0.000 description 1
- 230000016784 immunoglobulin production Effects 0.000 description 1
- 230000004957 immunoregulator effect Effects 0.000 description 1
- 229960003444 immunosuppressant agent Drugs 0.000 description 1
- 239000003018 immunosuppressive agent Substances 0.000 description 1
- 239000012535 impurity Substances 0.000 description 1
- 238000011534 incubation Methods 0.000 description 1
- 230000002757 inflammatory effect Effects 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- BPHPUYQFMNQIOC-NXRLNHOXSA-N isopropyl beta-D-thiogalactopyranoside Chemical compound CC(C)S[C@@H]1O[C@H](CO)[C@H](O)[C@H](O)[C@H]1O BPHPUYQFMNQIOC-NXRLNHOXSA-N 0.000 description 1
- 230000007803 itching Effects 0.000 description 1
- 150000002632 lipids Chemical class 0.000 description 1
- 239000002502 liposome Substances 0.000 description 1
- 239000000314 lubricant Substances 0.000 description 1
- 229940035034 maltodextrin Drugs 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 238000010297 mechanical methods and process Methods 0.000 description 1
- 229940062713 mite extract Drugs 0.000 description 1
- 230000000877 morphologic effect Effects 0.000 description 1
- 238000005457 optimization Methods 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 150000003904 phospholipids Chemical class 0.000 description 1
- 230000000704 physical effect Effects 0.000 description 1
- 239000006187 pill Substances 0.000 description 1
- 239000011148 porous material Substances 0.000 description 1
- 238000002360 preparation method Methods 0.000 description 1
- 239000012744 reinforcing agent Substances 0.000 description 1
- 210000002345 respiratory system Anatomy 0.000 description 1
- 238000003757 reverse transcription PCR Methods 0.000 description 1
- HFHDHCJBZVLPGP-UHFFFAOYSA-N schardinger α-dextrin Chemical compound O1C(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(O)C2O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC2C(O)C(O)C1OC2CO HFHDHCJBZVLPGP-UHFFFAOYSA-N 0.000 description 1
- 231100000004 severe toxicity Toxicity 0.000 description 1
- 230000035939 shock Effects 0.000 description 1
- 206010041232 sneezing Diseases 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 241000894007 species Species 0.000 description 1
- 238000010186 staining Methods 0.000 description 1
- 210000000130 stem cell Anatomy 0.000 description 1
- 238000010254 subcutaneous injection Methods 0.000 description 1
- 239000007929 subcutaneous injection Substances 0.000 description 1
- 239000000758 substrate Substances 0.000 description 1
- 239000005720 sucrose Substances 0.000 description 1
- 239000004094 surface-active agent Substances 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 208000011580 syndromic disease Diseases 0.000 description 1
- 230000009885 systemic effect Effects 0.000 description 1
- 239000003826 tablet Substances 0.000 description 1
- 229940124597 therapeutic agent Drugs 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 239000003053 toxin Substances 0.000 description 1
- 231100000765 toxin Toxicity 0.000 description 1
- 108700012359 toxins Proteins 0.000 description 1
- 238000004627 transmission electron microscopy Methods 0.000 description 1
- 230000029069 type 2 immune response Effects 0.000 description 1
- 210000003556 vascular endothelial cell Anatomy 0.000 description 1
- 229940118696 vibrio cholerae Drugs 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/1767—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from invertebrates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/02—Bacterial antigens
- A61K39/025—Enterobacteriales, e.g. Enterobacter
- A61K39/0258—Escherichia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/66—Microorganisms or materials therefrom
- A61K35/74—Bacteria
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/02—Bacterial antigens
- A61K39/025—Enterobacteriales, e.g. Enterobacter
- A61K39/0275—Salmonella
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/35—Allergens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0043—Nose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
- A61K9/127—Liposomes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/52—Bacterial cells; Fungal cells; Protozoal cells
- A61K2039/523—Bacterial cells; Fungal cells; Protozoal cells expressing foreign proteins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
- A61K2039/55555—Liposomes; Vesicles, e.g. nanoparticles; Spheres, e.g. nanospheres; Polymers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Abstract
【選択図】図15
Description
北アメリカ家塵ダニの主なアレルゲンであるDer f2クローニングのためにDer f2遺伝子(reference sequence:GeneBank AB195580)をのcDNAをRT−PCR法により合成した。PCR産物は、T−blunt PCRベクター(T−blunt PCR cloning kit、Solgent)に挿入した後、それぞれのプラスミドをEcoRI(OmpA、ABC transporter)およびBglII(FepA)で切断した。切片を電気泳動で分離した後、pET−30aプラスミドに挿入し、大腸菌DH5aにヒートショック法で形質転換して、最終的に前記遺伝子をクローニングした。
実施例1で得たDer f2抗原がローディングされた細胞外小胞をPBSで希釈(50μg/ml)させ、300メッシュのCuグリッド(EMS)に10μlローディングした。陰性染色(negative stain)のためにウラニルアセテート(2%)をグリッドに落とし、JEM1011電子顕微鏡(JEOL)で観察した。その結果、図2に示されたように、前記細胞外小胞は、球形であって、脂質二重層で囲まれていることを確認した。
Der f2抗原がローディングされた細胞外小胞を免疫調節剤として利用するためには、免疫反応を誘導できなければならないので、Der f2抗原がローディングされた細胞外小胞による先天性免疫反応誘導水準を評価するために、骨髄細胞に由来する樹枝状細胞(bone marrow−derived dendritic cell、BMDC)を使用してin vitro実験を行った。
Hfq−結合sRNAのうち種保存性に優れたsRNAを活用して大腸菌sRNA塩基配列と同じMic A sRNA(CATCTCTGAATTCAGGGATGATGATAACAAATGCGCGTCTTT)が含まれたpBRplac−sRNAプラスミドをサルモネラ菌に導入した。具体的に、サルモネラチフィムリウム(Salmonella Typhimurium)14028S種にpBRplac−sRNAを電気穿孔法(electroporation)を利用して導入した。
サルモネラ菌株は、腸炎を誘発してTh1免疫反応を誘導することが知られている。これにより、sRNA過発現を通じて得た細胞外小胞のTh1免疫反応誘導能を確認した。具体的に、グループ当たり5個体のマウス(C67BL/6)に腹腔経路を通じて細胞外小胞100ug/hdを2日間隔で投与した。そして、5日目になる日に解剖して腹腔内リンパ節から細胞を分離した後、抗−CD3およびCD28を使用して12時間T細胞再刺激を実施した後、T細胞で分泌されるサイトカイン量を測定した。
サルモネラ菌由来小胞自体は、免疫原性が良いが、細胞外膜に存在するLPSによる毒性が問題になる。これを解決するための方案として、LPSの活性を抑制するPMBをMic A sRNA過発現サルモネラ菌由来小胞と混ぜて先天性免疫反応誘導水準を評価した。
生体内(in vivo)でDer f2抗原がローディングされた細胞外小胞による抗体免疫反応誘導能を確認し、Der f2抗原がローディングされた細胞外小胞の有効量を決定するために、Der f2抗原がローディングされた細胞外小胞をマウスに投与して免疫を誘導した。また、免疫反応を誘導した後、対照群(PBS)およびDer f2抗原がローディングされた細胞外小胞を投与したマウスから血液を採取してDer f2特異的IgG抗体を測定し、気管支肺胞洗浄液を採取してDer f2特異的sIgA抗体の濃度を測定した。
生体内(in vivo)でDer f2抗原がローディングされた細胞外小胞を投与して免疫反応を誘導した後、対照群(PBS)およびDer f2抗原がローディングされた細胞外小胞を投与したマウスにおいてT細胞で生成されるサイトカインの量を測定してT細胞反応を評価した。
家塵ダニアレルゲンで誘導されたマウス喘息モデルにおいてDer f2抗原がローディングされた細胞外小胞の効能を評価するために、次のような実験を行った(図14参照)。図14に示されたように、喘息モデルを製作するために北アメリカ家塵ダニからアレルゲンを抽出した後、アレルゲン75μgにalumを混ぜて腹腔に2回投与した後、アレルゲン50μgを単独で2回鼻腔に投与して喘息モデルを製作した(図14参照)。
Claims (11)
- 細菌由来細胞外小胞を有効成分として含有するアレルギー疾患予防または治療用薬学的組成物であって、前記細菌は、家塵ダニ由来アレルゲン遺伝子を過発現させた細菌であり、前記アレルギー疾患は、家塵ダニ由来アレルゲンによるアレルギー疾患であることを特徴とする、薬学的組成物。
- 前記細菌は、大腸菌(E.coli)またはサルモネラ菌であることを特徴とする、請求項1に記載の薬学的組成物。
- 前記家塵ダニは、ヨーロッパ家塵ダニ(Dermatophagoides pteronyssinus)または北アメリカ家塵ダニ(Dermatophagoides farinae)であることを特徴とする、請求項1に記載の薬学的組成物。
- 前記家塵ダニは、北アメリカ家塵ダニ(Dermatophagoides farinae)であることを特徴とする、請求項3に記載の薬学的組成物。
- 前記家塵ダニ由来アレルゲンは、Der p1、Der p2、Der p3、Der p4、Der p6、Der p9、Der p15、Der f1、Der f2、Der f11、およびDer f18よりなる群から選択されることを特徴とする、請求項1に記載の薬学的組成物。
- 前記家塵ダニ由来アレルゲンは、Der f2であることを特徴とする、請求項5に記載の薬学的組成物。
- (a)家塵ダニ由来アレルゲン遺伝子を細菌に過発現させる段階と;
(b)前記過発現された細菌を培養する段階と;
(c)前記細菌培養液から小胞を分離する段階と;
(d)前記細菌由来小胞の外膜内毒素の活性を除去する段階とを含む、家塵ダニ由来アレルゲンによるアレルギー疾患予防または治療用細菌由来小胞の製造方法であって、
前記(a)段階の家塵ダニ由来アレルゲンは、Der f2であることを特徴とする、方法。 - 前記家塵ダニは、北アメリカ家塵ダニ(Dermatophagoides farinae)であることを特徴とする、請求項7に記載の方法。
- 前記細菌は、大腸菌(E.coli)またはサルモネラ菌であることを特徴とする、請求項7に記載の方法。
- 請求項1に記載の薬学的組成物を個体に投与する段階を含む、アレルギー疾患の治療方法。
- 請求項1に記載の、薬学的組成物のアレルギー疾患予防または治療用途。
Applications Claiming Priority (5)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
KR10-2016-0005094 | 2016-01-15 | ||
KR20160005094 | 2016-01-15 | ||
KR10-2016-0145662 | 2016-11-03 | ||
KR1020160145662A KR101858840B1 (ko) | 2016-01-15 | 2016-11-03 | 집먼지진드기 유래 알레르겐에 의한 과민반응 면역조절제 |
PCT/KR2016/012626 WO2017122915A1 (ko) | 2016-01-15 | 2016-11-04 | 집먼지진드기 유래 알레르겐에 의한 과민반응 면역조절제 |
Publications (2)
Publication Number | Publication Date |
---|---|
JP2019501926A true JP2019501926A (ja) | 2019-01-24 |
JP6646155B2 JP6646155B2 (ja) | 2020-02-14 |
Family
ID=59422737
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2018536115A Active JP6646155B2 (ja) | 2016-01-15 | 2016-11-04 | 家塵ダニ由来アレルゲンによる過敏反応免疫調節剤 |
Country Status (5)
Country | Link |
---|---|
US (1) | US11065300B2 (ja) |
EP (1) | EP3403670B1 (ja) |
JP (1) | JP6646155B2 (ja) |
KR (1) | KR101858840B1 (ja) |
CN (1) | CN108697784B (ja) |
Families Citing this family (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2020252149A1 (en) * | 2019-06-11 | 2020-12-17 | Evelo Biosciences, Inc. | Processed microbial extracellular vesicles |
Citations (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2005514388A (ja) * | 2001-12-17 | 2005-05-19 | ヘルス プロテクション エージェンシー | グラム陰性菌由来の外膜小胞およびワクチンとしての使用 |
JP2007534667A (ja) * | 2004-02-02 | 2007-11-29 | エンジェネイック モレキュラー デリバリー ピーティーワイ リミテッド | 細菌由来のインタクトなミニ細胞を介した哺乳動物細胞への標的化invitro及びinvivo薬物送達のための組成物及び方法 |
JP2008519776A (ja) * | 2004-11-10 | 2008-06-12 | アルク−アベッロ エイ/エス | アレルギーワクチンの粘膜投与によるアレルギーの予防治療方法 |
JP2013507354A (ja) * | 2009-10-08 | 2013-03-04 | イオン メディックス インコーポレイテッド | 室内空気由来細胞外ベシクルを含む組成物及びその用途 |
JP2013534830A (ja) * | 2010-07-01 | 2013-09-09 | イオン メディックス インコーポレイテッド | 細胞の原形質体に由来するマイクロベシクル及びその用途 |
WO2014095866A1 (en) * | 2012-12-17 | 2014-06-26 | Eurocine Vaccines Ab | Intranasal vaccination dosage regimen |
JP2015057393A (ja) * | 2007-08-15 | 2015-03-26 | サーカッシア リミテッド | アレルゲンに対する脱感作のためのペプチド |
WO2015112485A1 (en) * | 2014-01-21 | 2015-07-30 | Immune Design Corp. | Compositions for use in the treatment of allergic conditions |
JP2015164424A (ja) * | 2008-03-25 | 2015-09-17 | ビアル インドゥストリアル ファルマセウティカ エス.エー.Bial Industrial Farmaceutica S.A. | アレルギーの治療に用いるための、主要グループ1ダニアレルゲンおよび主要グループ2ダニアレルゲンの低アレルゲン性ハイブリッドタンパク質 |
Family Cites Families (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5371186A (en) * | 1991-02-11 | 1994-12-06 | Biosynth S.R.L. | Synthetic peptides for detoxification of bacterial endotoxins and for the prevention and treatment of septic shock |
CA2550927A1 (en) * | 2003-12-23 | 2005-07-14 | Glaxosmithkline Biologicals S.A. | A gram negative bacterium with reduced lps level in the outer membrane and use thereof for treating gram negative bacterial infection |
CN113046285A (zh) * | 2012-04-06 | 2021-06-29 | 康奈尔大学 | 用于稳健的体液及细胞免疫应答的亚单位疫苗递送平台 |
CN104602702B (zh) * | 2012-09-18 | 2021-08-27 | 葛兰素史密丝克莱恩生物有限公司 | 外膜囊泡 |
CN103642815A (zh) * | 2013-12-04 | 2014-03-19 | 江南大学 | 一种分泌表达屋尘螨过敏原Derp2的重组乳酸乳球菌及其应用 |
US10258683B2 (en) * | 2015-05-27 | 2019-04-16 | George Mason University | Engineered vesicles comprising antigenic peptides and the uses thereof as modulators of immune responses |
-
2016
- 2016-11-03 KR KR1020160145662A patent/KR101858840B1/ko active IP Right Grant
- 2016-11-04 US US16/070,220 patent/US11065300B2/en active Active
- 2016-11-04 JP JP2018536115A patent/JP6646155B2/ja active Active
- 2016-11-04 CN CN201680078791.7A patent/CN108697784B/zh active Active
- 2016-11-04 EP EP16885226.7A patent/EP3403670B1/en active Active
Patent Citations (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2005514388A (ja) * | 2001-12-17 | 2005-05-19 | ヘルス プロテクション エージェンシー | グラム陰性菌由来の外膜小胞およびワクチンとしての使用 |
JP2007534667A (ja) * | 2004-02-02 | 2007-11-29 | エンジェネイック モレキュラー デリバリー ピーティーワイ リミテッド | 細菌由来のインタクトなミニ細胞を介した哺乳動物細胞への標的化invitro及びinvivo薬物送達のための組成物及び方法 |
JP2008519776A (ja) * | 2004-11-10 | 2008-06-12 | アルク−アベッロ エイ/エス | アレルギーワクチンの粘膜投与によるアレルギーの予防治療方法 |
JP2015057393A (ja) * | 2007-08-15 | 2015-03-26 | サーカッシア リミテッド | アレルゲンに対する脱感作のためのペプチド |
JP2015164424A (ja) * | 2008-03-25 | 2015-09-17 | ビアル インドゥストリアル ファルマセウティカ エス.エー.Bial Industrial Farmaceutica S.A. | アレルギーの治療に用いるための、主要グループ1ダニアレルゲンおよび主要グループ2ダニアレルゲンの低アレルゲン性ハイブリッドタンパク質 |
JP2013507354A (ja) * | 2009-10-08 | 2013-03-04 | イオン メディックス インコーポレイテッド | 室内空気由来細胞外ベシクルを含む組成物及びその用途 |
JP2013534830A (ja) * | 2010-07-01 | 2013-09-09 | イオン メディックス インコーポレイテッド | 細胞の原形質体に由来するマイクロベシクル及びその用途 |
WO2014095866A1 (en) * | 2012-12-17 | 2014-06-26 | Eurocine Vaccines Ab | Intranasal vaccination dosage regimen |
WO2015112485A1 (en) * | 2014-01-21 | 2015-07-30 | Immune Design Corp. | Compositions for use in the treatment of allergic conditions |
Also Published As
Publication number | Publication date |
---|---|
EP3403670A1 (en) | 2018-11-21 |
CN108697784B (zh) | 2022-02-01 |
KR101858840B1 (ko) | 2018-05-16 |
EP3403670A4 (en) | 2019-06-26 |
CN108697784A (zh) | 2018-10-23 |
US20190247465A1 (en) | 2019-08-15 |
KR20170085943A (ko) | 2017-07-25 |
US11065300B2 (en) | 2021-07-20 |
EP3403670B1 (en) | 2022-09-14 |
JP6646155B2 (ja) | 2020-02-14 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
Prado et al. | Exosomes from bronchoalveolar fluid of tolerized mice prevent allergic reaction | |
IL276798A (en) | Preparations containing bacterial strains | |
US8404250B2 (en) | Gram positive bacteria preparations for the treatment of diseases comprising an immune dysregulation | |
Peron et al. | Oral tolerance reduces Th17 cells as well as the overall inflammation in the central nervous system of EAE mice | |
US20090169582A1 (en) | Recombinant lactobacillus and use of the same | |
CN113677328A (zh) | 细菌来源的囊泡及其用途 | |
Meechan et al. | Intranasal, liposome-adjuvanted cockroach allergy vaccines made of refined major allergen and whole-body extract of Periplaneta americana | |
Aso et al. | Adipose-derived mesenchymal stem cells restore impaired mucosal immune responses in aged mice | |
Joo et al. | Critical role of TSLP-responsive mucosal dendritic cells in the induction of nasal antigen-specific IgA response | |
JP6243367B2 (ja) | 分類不能(non−typeable)インフルエンザ菌(Haemophilusinfluenzae)ワクチンおよびその使用 | |
Levit et al. | Use of genetically modified lactic acid bacteria and bifidobacteria as live delivery vectors for human and animal health | |
JP6646155B2 (ja) | 家塵ダニ由来アレルゲンによる過敏反応免疫調節剤 | |
KR102186420B1 (ko) | 스타필로코커스 석시너스 14bme20 균주를 유효성분으로 포함하는 알레르기 질환의 예방, 개선 또는 치료용 조성물 | |
Ai et al. | Mucosal delivery of allergen peptides expressed by Lactococcus lactis inhibit allergic responses in a BALB/c mouse model | |
KR101745809B1 (ko) | 세포밖 소포 생성 및 숙주 면역반응을 조절하는 Small RNA 유전자 및 이의 용도 | |
KR101911893B1 (ko) | 세균유래 세포밖 소포에 의한 기도 면역기능이상 조절제 | |
Yu et al. | Lactobacillus casei ghosts as a vehicle for the delivery of DNA vaccines mediate immune responses | |
Lee et al. | Vibrio vulnificus infection induces the maturation and activation of dendritic cells with inflammatory Th17-polarizing ability | |
Albright et al. | Endogenous antigen presenting cell-derived IL-10 inhibits T lymphocyte responses to commensal enteric bacteria | |
WO2017123025A1 (ko) | 세균유래 세포밖 소포에 의한 기도 면역기능이상 조절제 | |
Zhang | Research progress on the role of immune cells in Brucella infection | |
WO2017122915A1 (ko) | 집먼지진드기 유래 알레르겐에 의한 과민반응 면역조절제 | |
Pavkova et al. | Protective Potential of Outer Membrane Vesicles Derived from Virulent Strain of Francisella tularensis | |
Kuria et al. | Cellular responses against Schistosoma mansoni in immunized Balb/c mice with soluble proteins from intermediate host, Biomphalaria pfeifferi | |
KR20170011221A (ko) | 클렙시엘라균 감염질환의 예방용 백신 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20180710 |
|
A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20180710 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20190521 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20190725 |
|
TRDD | Decision of grant or rejection written | ||
A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20191217 |
|
A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20200109 |
|
R150 | Certificate of patent or registration of utility model |
Ref document number: 6646155 Country of ref document: JP Free format text: JAPANESE INTERMEDIATE CODE: R150 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |